• p53/PUMA-Mediated Synthetic Lethality via WRN Inhibition in

  2026-05-11

  This study uncovers how depletion or inhibition of Werner (WRN) helicase triggers p53/PUMA-dependent apoptosis specifically in mismatch repair-deficient (MSI) colorectal cancer cells. The mechanistic findings establish WRN as a promising therapeutic vulnerability in p53-wildtype MSI CRC, informing targeted DNA repair enzyme inhibitor strategies.

• Food-Grade Nanoparticle Assembly for Enhanced Nutraceutical

  2026-05-11

  This study introduces Facilitated Self-Assembling Technology (FAST), a food-grade platform enabling the production of stable, surfactant-free nutraceutical nanoparticles with improved solubility and bioavailability. The research demonstrates that FAST formulations offer rapid, scalable, and biocompatible delivery of hydrophobic bioactives, suggesting a significant advance for next-generation nutritional supplements and functional beverages.

• Bedaquiline: Diarylquinoline Antibiotic Workflows in TB & Ca

  2026-05-10

  Bedaquiline, a diarylquinoline antibiotic from APExBIO, revolutionizes both multi-drug resistant tuberculosis treatment and cancer stem cell research through its dual inhibition of bacterial ATP synthase and cancer cell metabolism. This article decodes detailed protocols, advanced applications, and troubleshooting strategies to accelerate high-impact translational studies.

• Optimizing hiPSC Platelet Differentiation with Small Molecul

  2026-05-09

  This study presents an advanced, cost-effective protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs) by refining culture conditions and strategically replacing cytokines with small-molecule modulators. The innovation accelerates differentiation time, increases platelet yield, and reduces production costs, offering new scalable possibilities for transfusion medicine and regenerative therapies.

• (S)-(+)-Dimethindene maleate: Technical Guidance for M2 Anta

  2026-05-08

  (S)-(+)-Dimethindene maleate enables selective interrogation of M2 muscarinic receptor pathways in autonomic regulation, cardiovascular physiology, and respiratory system research. It is not suited for diagnostic or therapeutic use, and strict adherence to product handling and preparation protocols is required for reliable results.

• ML216, BLM Helicase Inhibitor: Precision Tools for DNA Repai

  2026-05-08

  ML216, a potent BLM helicase inhibitor, empowers precise DNA repair pathway interrogation and synthetic lethality experiments in oncology research. This guide details optimized workflows, troubleshooting tactics, and translational insights, setting ML216 apart for robust homologous recombination and tumor cell sensitization studies.

• MitMAB: Strategic Inhibition of Endocytosis in Organoid Rese

  2026-05-07

  This thought-leadership article explores how MitMAB (N,N,N-trimethyltetradecan-1-aminium bromide) enables precise mechanistic dissection of endocytosis in physiologically relevant intestinal stem cell organoid models. Blending mechanistic insight with actionable protocol guidance, we contextualize MitMAB’s competitive advantages, its role in translational research, and its contribution to decoding extracellular vesicle uptake. Drawing on recent literature, including studies on milk-derived extracellular vesicle internalization, we position MitMAB as an indispensable tool for next-generation membrane trafficking research.

• Blocking TLR4 Prevents Posttraumatic Epileptogenesis in Mice

  2026-05-07

  This study demonstrates that inhibition of TLR4 or RAGE signaling pathways effectively prevents the development of posttraumatic epilepsy in a mouse model. Early blockade post-injury reduced spontaneous seizures and neuroinflammation, highlighting a promising approach for secondary epilepsy prevention.

• Dissecting In Vitro Drug Response: Lessons from Schwartz et

  2026-05-06

  Schwartz et al. (2022) provide a rigorous analysis of how in vitro assays distinguish between proliferative arrest and cell death when evaluating anti-cancer drugs. Their methodological innovation—separating relative and fractional viability—clarifies mechanistic drug effects and informs best practices for preclinical screening, with direct implications for studies of cell cycle checkpoint inhibitors like MK-1775.

• Meropenem Trihydrate: Metabolomic Insights for Resistance Re

  2026-05-06

  Explore how Meropenem trihydrate empowers antibiotic resistance studies through advanced metabolomic profiling, enabling rapid, data-driven decisions in infection research. This article delivers a deeper, practical look at integrating carbapenem antibiotics into cutting-edge workflows.

• ECL Chemiluminescent Substrate Detection Kit: Enabling Quant

  2026-05-05

  Explore how the ECL Chemiluminescent Substrate Detection Kit (Enhanced) empowers advanced, quantitative protein immunodetection in cancer metabolism research. This article uniquely integrates substrate performance with mechanistic insights from recent RCC studies, offering protocol clarity and scientific depth.

• Targeted Non-Viral Gene Delivery to Adipocytes via ATS-9R

  2026-05-05

  Won et al. introduce ATS-9R, a non-viral fusion oligopeptide that enables highly selective gene delivery to adipocytes by leveraging Prohibitin-mediated endocytosis. This approach demonstrates effective gene silencing in adipose tissue, offering a safer and more targeted alternative for obesity and metabolic disease research.

• Vemurafenib (PLX4032): Mechanisms, Resistance, and New Front

  2026-05-04

  This article offers translational researchers an advanced, systems-level perspective on deploying Vemurafenib (PLX4032) in melanoma research. By integrating mechanistic insight, multi-omics resistance mapping, and strategic guidance, it bridges product intelligence with actionable experimental design, spotlighting ARID1A-dependent resistance and outlining the evolving landscape of targeted melanoma therapy.

• NSC-23766: Rac GTPase Inhibitor for Cancer Research Workflow

  2026-05-04

  NSC-23766 trihydrochloride stands out as a selective Rac1 signaling pathway inhibitor, enabling precise modulation of cell cycle, apoptosis, and barrier function in cancer and stem cell research. This article translates the latest mechanistic findings into actionable protocols and troubleshooting solutions for advanced experimental design.

• Vaccinia Virus F1L Inhibits ZAKα-Mediated NLRP1 Inflammasome

  2026-05-03

  This study uncovers how the vaccinia virus F1L protein blocks NLRP1 inflammasome activation by targeting the ribotoxic stress response, particularly ZAKα signaling. The findings clarify a sophisticated viral immune evasion mechanism and provide a robust experimental framework for dissecting inflammasome regulation in epithelial cells.

11384 records 1/759 page Next 12345 下5页 Last page